# OnCo record nct05100862 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct05100862/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct05100862", "NCT05100862" ;
  schema:name "A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphom"@en ;
  schema:alternateName "MAHOGANY"@en ;
  schema:description "A phase 3 trial of Zanubrutinib, Rituximab, Lenalidomide in follicular lymphoma, run by BeOne Medicines, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct05100862/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05100862> ;
  onco:status "active" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2022-03-10" ;
  onco:cancers <https://onco.cc/cancers/follicular-lymphoma/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/monoclonal-antibody/>, <https://onco.cc/technologies/protac-degrader/> ;
  onco:drugs <https://onco.cc/drugs/zanubrutinib/>, <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/lenalidomide/>, <https://onco.cc/drugs/obinutuzumab/> ;
  onco:companies <https://onco.cc/companies/beone/> .